News · Heart & Metabolic
Benefits of a type 1 diabetes pill faded within a year of patients stopping it
Baricitinib preserved insulin production in newly diagnosed type 1 diabetes, raising hopes of a course of treatment rather than a lifetime of it. Following 88 patients after the drug stopped answered that.
- Insulin production stayed higher for about six months after stopping, then converged.
- By a year off the drug there was no measurable advantage left.
- Insulin doses and long-term glucose control showed no lasting difference either.
- Adults appeared to hold their gains at the point of stopping; children did not.
- 88 of 91 randomized participants completed follow-up, so the trial is small.
The most valuable thing a person with newly diagnosed type 1 diabetes still has is the insulin they are making themselves.
It is running out, which is the nature of the disease, but the remainder is not merely sentimental. People who hold onto some of their own production have steadier glucose, fewer dangerous lows and fewer complications decades later. Protecting what is left has been the central ambition of immune treatment in this condition for forty years.
Baricitinib appeared to do it. A trial found that taking it for 48 weeks preserved insulin production and lowered insulin requirements, and the obvious next question was whether the benefit outlasted the pills.
What was asked
Writing in Diabetes Care, the trial investigators followed participants for another 48 weeks after the drug was withdrawn.
They measured how much insulin people were still producing, how much they were injecting, their longer-term glucose control, and the behavior of the immune cells thought to be driving the attack.
What happened
At roughly six months off the drug, the treated group was still ahead. Insulin production remained measurably higher than in those who had received placebo.
By a year off it, that gap was gone.
Insulin doses did not differ. Long-term glucose control did not differ. The continuous monitoring measures did not differ. And the immune changes seen during treatment, a reduction in the frequency and signaling of the cells implicated in the disease, had resolved as well.
The conclusion the authors draw
They state it without softening: the benefits of oral baricitinib in type 1 diabetes wane over the 48 weeks following treatment cessation, and durable benefit is likely to require continuous treatment.
That is a real disappointment, and it is worth being clear about what kind. The drug is not being reported as ineffective. It worked while people took it. What has failed is the more attractive possibility, that a defined course could interrupt the disease and leave a lasting change behind.
Why the immune finding matters most
The treated group’s immune profile returned to where it started.
If the drug had reset something, you would expect the immune signature to stay shifted after the pills stopped. Instead it drifted back, and the insulin production drifted back with it.
That is a coherent account of a suppressive rather than a curative effect. Remove the suppression and the process it was holding down resumes.
The adults and the children
A post hoc comparison found that adults who stopped at 48 weeks appeared to hold their insulin production while children declined.
That is interesting and should be held loosely. Post hoc comparisons in small subgroups are where spurious findings live, the numbers involved are small, and children have more aggressive disease at diagnosis for reasons that predate any drug.
If it survives a proper test, it would matter a great deal for who is offered this kind of treatment and for how long.
The size of it
91 people randomized, 88 followed to the end. That is small, and it is small in the direction that matters here, because the finding rests partly on the absence of differences.
A study this size can miss a modest lasting benefit. What it can say is that nothing large persisted.
What it means for the field
With type 1 diabetes, your body makes little or no insulin, and immune treatments aim to slow the loss rather than restore it.
This result reframes what such treatments are. Not a course of therapy, but something closer to ongoing management, with everything that implies about cost, adherence and long-term safety in people who may start young. That is a harder proposition than the trial’s first result suggested, and it is better to know it now.
People also ask
What did the analysis find?
Of 91 randomized participants, 88 (58 baricitinib and 30 placebo) completed week 96 follow-up. Mean C-peptide was significantly greater in baricitinib-treated participants at week 72 (0.54 vs 0.38 pmol/mL; P = 0.015) but not at week 96 (P = 0.336). No significant between-group differences in insulin dose, HbA1c or continuous glucose monitoring measures were observed during follow-up.
What is C-peptide and why measure it?
A fragment released in equal amounts to insulin when the pancreas makes it. Because injected insulin contains no C-peptide, measuring it shows how much insulin a person is still producing themselves, which injected insulin would otherwise mask.
What is baricitinib?
An oral drug that dampens certain immune signaling pathways, already used in rheumatoid arthritis and some other conditions. In type 1 diabetes the idea is to interrupt the immune attack on the insulin-producing cells.
Why does preserving any insulin production matter?
Because people who retain some of their own insulin have steadier glucose, fewer severe low episodes and fewer long-term complications. It is not a cure, and it makes the disease meaningfully easier to live with.
What was the difference between adults and children?
In a post hoc comparison, adults who stopped the drug appeared to hold their insulin production steady while children declined. Post hoc comparisons in small subgroups are exploratory and this one needs testing directly before it is relied on.
Does this mean the drug failed?
No. It worked while taken. What failed is the hope that a finite course would produce a lasting change, which is a different and more disappointing result for anyone hoping to avoid indefinite treatment.
What does this mean for someone recently diagnosed?
Nothing changes in current care; this drug is not approved for type 1 diabetes and was given in a trial. Treatment decisions belong with a diabetes specialist. This is general information rather than medical advice.